Inhibition of Phosphatidylinositol 3-Kinase Activity by Adenovirus-mediated Gene Transfer and Its Effect on Insulin Action*

Prem M. SharmaDagger , Katsuya EgawaDagger , Yi HuangDagger , Jody L. MartinDagger , Ivana Huvar§, Gerry R. Boss§, and Jerrold M. OlefskyDagger parallel **

From the Dagger  Department of Medicine, Division of Endocrinology and Metabolism, the parallel  Whittier Diabetes Institute, and the § Department of Medicine, University of California, San Diego, La Jolla, California 92093, the  Veterans Administration Research Service, San Diego, California 92161

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Phosphatidylinositol 3-kinase (PI 3-K) is implicated in cellular events including glucose transport, glycogen synthesis, and protein synthesis. It is activated in insulin-stimulated cells by binding of the Src homology 2 (SH2) domains in its 85-kDa regulatory subunit to insulin receptor substrate-1 (IRS-1), and, others. We have previously shown that IRS-1-associated PI 3-kinase activity is not essential for insulin-stimulated glucose transport in 3T3-L1 adipocytes, and that alternate pathways exist in these cells. We now show that adenovirus-mediated overexpression of the p85N-SH2 domain in these cells behaves in a dominant-negative manner, interfering with complex formation between endogenous PI 3-K and its SH2 binding targets. This not only inhibited insulin-stimulated IRS-1-associated PI 3-kinase activity, but also completely blocked anti-phosphotyrosine-associated PI 3-kinase activity, which would include the non-IRS-1-associated activity. This resulted in inhibition of insulin-stimulated glucose transport, glycogen synthase activity and DNA synthesis. Further, Ser/Thr phosphorylation of downstream molecules Akt and p70 S6 kinase was inhibited. However, co-expression of a membrane-targeted p110C with the p85N-SH2 protein rescued glucose transport, supporting our argument that the p85N-SH2 protein specifically blocks insulin-mediated PI 3-kinase activity, and, that the signaling pathways downstream of PI 3-kinase are intact. Unexpectedly, GTP-bound Ras was elevated in the basal state. Since p85 is known to interact with GTPase-activating protein in 3T3-L1 adipocytes, the overexpressed p85N-SH2 peptide could titrate out cellular GTPase-activating protein by direct association, such that it is unavailable to hydrolyze GTP-bound Ras. However, insulin-induced mitogen-activated protein kinase phosphorylation was inhibited. Thus, PI 3-kinase may be required for this action at a step independent of and downstream of Ras. We conclude that, in 3T3-L1 adipocytes, non-IRS-1-associated PI 3-kinase activity is crucial for insulin's metabolic signaling, and that overexpressed p85N-SH2 protein inhibits a variety of insulin's ultimate biological effects.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Insulin binding to its cell surface receptors initiates diverse metabolic and mitogenic signals by activation of a complex signaling cascade of protein tyrosine and serine/threonine kinases, as well as lipid kinases (1, 2). Phosphatidylinositol (PI)1 3-kinase (PI 3-kinase), a dual protein and lipid kinase is a heterodimeric enzyme composed of a 110-kDa catalytic subunit (p110) associated with an 85-kDa regulatory subunit (p85). Two isoforms of the catalytic subunit (p110alpha and p110beta ) and several isoforms of the regulatory subunit (p55alpha , p55PIK, p85alpha , and p85beta ) have been cloned so far. The regulatory subunit contains several well known functional domains: one Src homology 3 (SH3) domain, homology to the breakpoint cluster region (bcr) gene, two proline-rich motifs, and two Src homology region 2 (SH2) domains (3). The p85alpha isoform is insulin-responsive and is predominantly expressed in 3T3-L1 adipocytes (4).

The insulin receptor is a tyrosine kinase, which, when activated by insulin, phosphorylates cellular substrates such as IRS-1, IRS-2, IRS-3, IRS-4 and the protein Shc, etc. (5-8). IRS-1 is the most well characterized among members of the IRS family. Following insulin stimulation, the phosphorylated YXXM motifs in IRS-1 binds to the SH2 domains of p85 stimulating the lipid kinase activity of the p110 subunit. Through the same SH2 mechanism, PI 3-kinase can associate with other proteins such as IRS-2-4, and the insulin receptor itself (9, 10). PI 3-kinase phosphorylates phosphatidylinositol (PI), phosphatidylinositol-4-monophosphate, and phosphatidylinositol-4,5-bisphosphate on the D-3 position of the inositol ring producing phosphatidylinositol 3-monophosphate, phosphatidylinositol 3,4-bisphosphate, and phosphatidylinositol 3,4,5-triphosphate, respectively. Insulin induces the production of D3-phosphorylated phosphoinositides through stimulation of PI 3-kinase activity in various tissues and cultured cells.

Insulin is a pleiotropic hormone that initiates a variety of biologic effects through a complex set of signaling cascades. As a general view, however, two main branches of the insulin signaling pathway can be activated in most cell types: one is controlled predominantly by PI 3-kinase (1, 11) and the other by the small GTP-binding protein p21ras (1). The major route by which insulin stimulates PI 3-kinase activity is through tyrosine phosphorylation of IRS-1, as described above. Insulin stimulates Ras activity through a dual mechanism involving Shc, and to a lesser extent, IRS-1, which subsequently binds to the Grb2·SOS complex, activating p21ras (12). Stimulated Ras then activates a cascade of protein serine/threonine kinases which includes Raf, MEK, and the mitogen-activated protein (MAP) kinases, ERK1 and ERK2 (reviewed in Refs. 1, 5, and 6). Activation of both of these pathways appears to be necessary for the mitogenic effects of insulin (12, 14, 15), whereas the metabolic effects of insulin are primarily activated by PI 3-kinase-dependent steps (16, 17). Thus, it has been shown that activated PI 3-kinase is both necessary and sufficient for insulin-stimulated GLUT4 translocation and glucose uptake (18-23), and downstream targets of PI 3-kinase such as AKT and p70 S6 kinase may play important roles in the ultimate metabolic actions of this hormone (24, 25).

By no means are the PI 3-kinase and Ras/MAP kinase pathways completely separate. For example, Yamauchi et al. (26) have demonstrated that PI 3-kinase may lie upstream of Ras and Raf in mediating mitogenic effects of insulin. On the other hand, experiments using wortmannin to inhibit PI 3-kinase activity have shown that the effect of insulin on p21ras·GTP loading in CHO cells is independent of PI 3-kinase (27). However, reciprocal relationships between PI 3-kinase and p21ras have also been demonstrated (28). Thus, one report has shown that activated Ras can stimulate PI 3-kinase activity, whereas other investigators have shown that the biologic effects of constitutively activated PI 3-kinase are Ras-dependent (29). Thus, although the exact relationship between PI 3-kinase and p21ras is unclear, abundant data exist to indicate that they are interconnected in some way (30).

In the current studies, we have extensively evaluated the role of PI 3-kinase activity in a diverse array of insulin actions. Our approach was based upon the notion that cellular overexpression of the N-SH2 domain of the p85 subunit would disrupt complex formation between endogenous PI 3-kinase and its SH2 domain binding targets, such as IRS-1. This, in turn, would prevent insulin activation of PI 3-kinase enzymatic activity, allowing us to elucidate the biologic actions of this enzyme in insulin target cells such as 3T3-L1 adipocytes. Since gene transfer into 3T3-L1 adipocytes can be problematic, we elected to use recombinant adenovirus to achieve these goals. We (31), and others (32), have recently demonstrated that adenovirus mediated gene delivery allows high efficiency gene transduction and protein expression in terminally differentiated 3T3-L1 adipocytes. Thus, we prepared a recombinant adenovirus encoding the N-SH2 domain of the p85 alpha  subunit of PI 3-kinase in order to overexpress this protein domain within 3T3-L1 adipocytes. Using this approach, we have investigated the acute effects of interrupting p85 association with insulin-stimulated target proteins on the ultimate biologic effects of insulin.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Porcine insulin was kindly provided by Lilly. Mouse monoclonal anti-phosphotyrosine (PY-20), mouse monoclonal anti-ERK1, and the anti-Shc-SH2 antibodies were purchased from Transduction Laboratories. Anti-IRS-1 and anti-human S6 kinase (p70S6K) were from Upstate Biotechnology Inc. (UBI). Phosphospecific MAPK and p70S6K antibodies were from New England Biolabs, Inc. The goat polyclonal AKT (C-20) antibody of human origin, anti-Ras antibody (Y13-259), and horseradish peroxidase-linked anti-rabbit, -mouse, and -goat antibodies were purchased from Santa Cruz Biotechnology. Dulbecco's modified Eagle's medium, fetal bovine serum, restriction enzymes, and the random primer DNA labeling kit were purchased from Life Technologies, Inc. . All radioisotopes were obtained from NEN Life Science Products. Hoechst dye 33342 was obtained from Molecular Probes (Eugene, OR). XAR-5 film was obtained from Eastman Kodak. All other reagents and chemicals were purchased from Sigma.

Cell Culture-- 3T3-L1 cells were grown and maintained in DMEM high glucose containing 50 units/ml penicillin, 50 µg/ml streptomycin, and 10% fetal bovine serum in a 10% CO2 environment. The cells were allowed to grow 2 days postconfluence, then differentiated by addition of the same medium containing isobutylmethylxanthine (500 µM), dexamethasone (25 µM), and insulin (4 µg/ml) for 3 days and the medium containing insulin for 3 additional days. The medium was then changed every 3 days until the cells were fully differentiated, typically by 10 days. Prior to experimentation, the adipocytes were trypsinized and reseeded in the appropriate culture dishes. Rat 1 fibroblasts that had been stably transfected and that overexpress wild type human insulin receptor (HIRcB cells) were cultured as described previously (14). The Ad-E1A-transformed human embryonic kidney cell line 293 was cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.

Plasmid Construction-- The N-SH2 domain of P85alpha subunit of bovine PI 3-Kinase were amplified by polymerase chain reaction (PCR) using Pfu polymerase (Boehringer Mannheim, France) with the following primers (5' to 3'), using full-length P85alpha subunit as the template cDNA. ctagtctagagccgccaccatgGTATGAATAACAATATGTCCTTA (primer 1, sense), gccgaagcttCA*ATTCAGATCCTCTTCTGAGATGAGTTTTTGTTCATCTTCTTTGACAACTTGATCCT (primer 2, antisense), XbaI and HindIII; the 5' and the 3' cloning sites are underlined. The PCR products digested with XbaI and HindIII were cloned into pACCMVpLpA (vector containing ampicillin selection marker), digested with XbaI and HindIII. Kozak sequences including a methionine initiation codon (indicated in lowercase, bold letters) were inserted upstream of the 5' end of the sense (primer 1) PCR primer. The antisense PCR primer 2 (written above in 5' to 3' orientation) contained the Myc tag sequences (uppercase, bold), downstream of the homologous sequences for the N-SH2 domain, followed by a stop codon (*). The inserted fragment was in-frame with the initiation codon. The plasmids pAC-p85N-SH2 (395 bp, including the methionine and Myc) obtained by cloning the cDNA fragments was amplified with the primer set 1 and 2. This plasmid encodes the p85N-SH2 domain specific protein (encoding nucleotides 962-1320) of the bovine p85alpha protein. The nucleotide sequence of the cloned plasmid was verified by DNA sequence analysis using the 5' and the 3' end specific primers around the cloning sites (XbaI and HindIII) of the plasmid, pACCMVpLpA.

Preparation of Recombinant Adenovirus-- The recombinant adenovirus containing the cDNA encoding the p85N-SH2 domain of bovine p85alpha protein were isolated by homologous recombination using two plasmids, pACCMVpLpA (33) and pJM17 (34). The recombinant plasmids pAC-p85N-SH2 and pJM17 were purified and co-transfected into 293 cells. Since 293 cells were originally derived from adenovirus transformation, the missing E1 gene function of pJM17 is provided in trans. The resulting recombinant virus containing the p85N-SH2 domain of bovine p85alpha is denoted as Ad5-p85N-SH2, which is replication-defective (at least in cells lacking the E1 region of adenovirus), but fully infectious.

Detection of Recombinant Ad5-p85N-SH2 or Wild-type by PCR-- DNA templates for PCR were extracted from the supernatant of the culture medium (350 µl) of the 293 cells that were infected with each plaque isolates/viruses at multiplicity of infection (m.o.i.) of 50 plaque-forming units (pfu)/ml. A multiplex PCR was performed on one-tenth of virus DNA using E1A and E2B region specific primers (35) and analyzed for the presence of recombinant or wild type adenoviruses. The presence of p85N-SH2 domain specific cDNA inserts of bovine p85 in the recombinant virus was confirmed by PCR analysis of viral DNA with p85N-SH2 cDNA specific primers. One clone of each of the recombinant viruses were amplified further in 293 cells. Purification by cesium chloride centrifugation resulted in higher titer stocks of the recombinant viruses, typically 1-2 × 1010 pfu/ml as determined by limiting dilution. All recombinant adenoviruses were stored at -70 °C in phosphate-buffered saline (PBS) supplemented with 10% glycerol.

Cell Treatment-- HIRcB cells were transduced at a multiplicity of infection of 1-20 pfu/cell for 1 h with stocks of either a control recombinant adenovirus (Ad5-Ctrl/Ad5-CMV) containing the cytomegalovirus promoter, pUC 18 polylinker, and a fragment of the SV40 genome or the recombinant adenoviruses Ad5-p85N-SH2. 3T3-L1 adipocytes required either 10-fold more virus or longer infection time (14-16 h) than HIRcB cells to achieve >90% infection in a transient system. Transduced cells were incubated for 48-72 h at 37 °C in 5% CO2 and DMEM with 2% heat-inactivated serum in order to minimize cell division and to avoid a hormonal effect on gene expression and/or on the activities of overexpressed proteins, followed by incubation in the starvation media required for the assay. The experiments were performed 60-96 h after the viral incubation and were repeated three to five times. The efficiency of adenovirus mediated gene transfer was approximately 90% as measured by histocytochemical staining for beta -galactosidase (beta -gal) of the cells infected with a recombinant adenovirus Ad5-lacZ, containing the bacterial beta -galactosidase gene (data not shown). The survival of the differentiated 3T3-L1 adipocytes was unaffected by incubation of cells with the different adenovirus constructs since the total cell protein remained the same in infected or uninfected cells. However, the HIRcB cells demonstrated about 10% decrease in total cellular protein, thereby indicating inhibition of cell cycle progression.

RNA Extraction and Northern Blot Analysis-- Total RNA was isolated from the control (uninfected) and Ad5-p85N-SH2-infected cells as described elsewhere (36). Total RNA (15 µg) was denatured and electrophoresed on a 1% agarose, 6.6% formaldehyde gel and blotted onto a Hybond-N+ membrane. A 360-bp cDNA fragment of bovine p85N-SH2 domains was labeled with [alpha -32P]dCTP by random priming. Northern blot was hybridized with the labeled probe and washed as described previously (36). Ethidium bromide staining of the electrophoresed RNA was used to visualize the loading pattern. The autoradiograph was obtained after a 6-h exposure and analyzed with a desktop scanner (Hewlett Packard Scan Jet II P), utilizing a scan analysis program.

DNA Synthesis-- Cells were infected with the indicated adenoviruses at m.o.i. of 2.0 and 10 for 1 h at room temperature, serum-starved for 36 h, and stimulated with insulin (100 ng/ml) in the presence of BrdUrd for 16 h at 37 °C. They were then fixed and processed for immunofluorescence by sequential incubation with rat anti-BrdUrd antibody and rhodamine-conjugated anti-donkey antibody. Cells were counter stained with Hoechst stain to visualize nuclei. BrdUrd-incorporated cells were identified by the nuclear red rhodamine staining. An average of 200 cells per coverslip were counted. Results are expressed as the percentages of stained cells exhibiting nuclear fluorescence.

Phosphatidylinositol 3'-Kinase Activity-- In vitro phosphorylation of phosphatidylinositol was carried out in immune complexes as described previously (37). Cells were infected with Ad5-p85N-SH2 or Ad5-CMV (control), or Ad5-lacZ (control) at the indicated m.o.i. and time and grown in medium containing heat-inactivated serum (2%) for 48 h. Serum-starved (16 h) cells were incubated in the absence (basal) or presence of insulin (100 ng/ml) for 10 min, washed once with ice-cold PBS, lysed, and subjected to immunoprecipitation (400-500 µg of total protein) with antibodies to IRS-1 or to phosphotyrosine residues (2-4 µg), overnight at 4 °C. Immune complexes were precipitated from the supernatant with protein A-Sepharose (Sigma) and washed as described (37). The washed immune complexes were incubated with phosphatidylinositol (Avanti) and [gamma -32P]ATP (3000 Ci/mmol) for 10 min at room temperature. Reactions were stopped with 20 µl of 8 N HCl and 160 µl of CHCl3:methanol (1:1) and centrifuged, and the lower organic phase was removed and applied to a silica gel thin-layer chromatography (TLC) plate (Merck) that had been coated with 1% potassium oxalate. TLC plates were developed in CHCl3:CH3OH:H2O:NH4OH (60:47:11.3:2), dried, and visualized, and quantitated on a Molecular Dynamics PhosphorImager.

2-Deoxyglucose Transport-- The procedure for glucose transport was a modification of the methods described by Klip et al. (38). Differentiated 3T3-L1 adipocytes were infected with Ad5-p85N-SH2 or Ad5-LacZ/Ad5-CMV (controls) at the indicated m.o.i. for 12 to 6 h at 37 °C and grown in medium containing heat-inactivated serum (2%) for 48 h. Serum and glucose deprived cells were incubated in alpha -MEM in the absence (basal) or presence of 100 ng/ml insulin for 1 h at 37 °C. In another set of experiments, cells were incubated with 1, 10, and 100 ng/ml insulin for 1 h at 37 °C. Glucose uptake was determined in duplicate at each point after the addition of 10 µl of substrate ([2-3H]deoxyglucose/L-[14C]glucose, 0.1 µCi, final concentration 0.01 mmol/liter) to provide a concentration at which cell membrane transport is rate-limiting. The value for L-glucose was subtracted to correct each sample for the contributions of diffusion and trapping. Data are representative of three different observations and each value was corrected for protein content.

Western Blotting-- Differentiated 3T3-L1 adipocytes uninfected or infected with Ad5-p85N-SH2 or Ad5-CMV/Ad5-lacZ (negative control) were starved for 24 h in serum-free Cellgro media. The cells were stimulated with insulin (100 ng/ml or as indicated in the figure legend) for 5-30 min at 37 °C and lysed in a solubilizing buffer containing 30 mM Tris, 150 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM Na3VO4, pH 7.4, for 20 min at 4 °C. The cell lysates were centrifuged to remove insoluble materials. For Western blot analysis, whole cell lysates (60-80 µg of protein/lane) from the indicated cells were denatured by boiling in Laemmli sample buffer containing 100 mM dithiothreitol and resolved by SDS-PAGE. Gels were transferred to Immobilon-P by electroblotting in Towbin buffer containing 0.02% SDS and 20% methanol and immunoblotted with the indicated antibody. Blots were then incubated with horseradish peroxidase-linked second antibody followed by chemiluminescence detection, according to the manufacturer's instructions (Pierce).

Glycogen Synthase Activity-- Glycogen synthase activity was determined as described previously (39), with some modifications. Confluent 3T3-L1 adipocytes (six-well culture dishes) were infected with the indicated adenovirus as described above for 2-deoxyglucose (2-DOG) assay, starved for 3 h in glucose and serum free DMEM containing 0.1% bovine serum albumin and 2 mM sodium pyruvate. Following this, the cells were either preincubated with 30 µM MEK inhibitor and stimulated with 200 ng/ml insulin for additional 30 min in DMEM containing 0.1% bovine serum albumin, 5 mM glucose, 2 mM sodium pyruvate. The cells were rinsed thrice with ice-cold PBS and then lysed in 150 µl of homogenization buffer (50 mM Tris-HCl, 10 mM EDTA, 100 mM KF (pH 7.4)) using a sonicator. Homogenates were centrifuged at 4,000 rpm for 10 min at 4 °C. Thirty µl of homogenate (equivalent to 10 µg of protein) was added to 60 µl of preheated glycogen synthase assay buffer (10% oyster glycogen, 10 µM uridine 5'-diphosphoglucose, 50 mM Tris-HCl, 25 mM Na2SO4, 50 mM NaF, 27 mM EDTA, 0.3 µCi of UDP-[14C]glucose per ml (pH 7.6) with and without 10 mM D-glucose 6-phosphate). The mixture was incubated at 30 °C for 30 min. Seventy-five microliters of each reaction mixture was applied to Whatman no. 4 filter paper. The filters were air-dried and washed three times for 1 h each in 66% ethanol. The final wash was with 100% acetone. Filters were dried and placed in scintillation fluid for counting. Glycogen synthase activation was calculated by subtracting glucose 6-phosphate-independent activity from glucose 6-phosphate-dependent activity.

Ras GTP/GDP Assay-- Differentiated 3T3-L1 adipocytes were infected with Ad5-p85N-SH2, or Ad5-CT at 50 m.o.i. for 16 h at 37 °C and grown in medium containing heat-inactivated serum (2%) for 48 h. Following 24 h of serum starvation, the cells were stimulated with or without insulin (100 ng/ml) for 10 min, washed with PBS, scraped, and frozen at -70 °C immediately. Frozen cell pellets were extracted in ice-cold RIPA buffer (50 mM Hepes, pH 7.4, 10 mM MgCl2, 150 mM NaCl, 1% Nonidet P-40, 0.5 mM phenylmethylsulfonyl fluoride, and 10 µg/ml each of aprotinin, leupeptin, and pepstatin) by shaking for 5 min at 4 °C. The resulting cell extracts were centrifuged at 10,000 × g for 2 min. The supernatants were divided in half and either 3 µg of the anti-Ras antibody Y13-259 (Santa Cruz Biotechnology) or 3 µg of rat IgG (Cappel) were added. To both samples, goat anti-rat IgG and protein G-agarose were added as well as NaCl, sodium dodecyl sulfate (SDS), and deoxycholate to final concentrations of 500 mM, 0.05%, and 0.5%, respectively. The samples were shaken gently for 1 h at 4 °C and then the immunoprecipitates were washed four times in RIPA buffer containing 500 mM NaCl, 0.05% SDS, and 0.5% deoxycholate and two times in 20 mM TrisPO4, pH 7.4. The washed immunoprecipitates were resuspended in 30 µl of 5 mM TrisPO4, pH 7.4, 2 mM dithiothreitol, 2 mM EDTA (TED buffer), heated to 100 °C for 3 min, cooled on ice, and centrifuged at 10,000 × g for 2 min. The immunoprecipitates were washed with an additional 15 µl of TED buffer, which was combined with the first 30 µl of TED buffer and GTP and GDP were measured as described below.

GTP was converted to ATP using NDP kinase and ADP with the ATP measured in the luciferase/luciferin system according to the following reactions.
<UP>GTP</UP>+<UP>ADP</UP> <LIM><OP><ARROW>→</ARROW></OP><UL><UP> NDP kinase</UP></UL></LIM><UP> GDP</UP>+<UP>ATP</UP>
<UP><SC>Reaction</SC> 1</UP>
<UP>ATP</UP>+<UP>luciferin</UP> <LIM><OP><ARROW>→</ARROW></OP><UL><UP>luriferase</UP></UL></LIM><UP> oxyluciferin</UP>+<UP>AMP</UP>+<UP>PP<SUB>i</SUB></UP>+<UP>light</UP>
<UP><SC>Reaction</SC> 2</UP>

PPi is pyrophosphate. This assay is sensitive to 1 fmol of GTP and was performed essentially as described previously (40). GDP was converted to GTP using pyruvate kinase and phosphoenolpyruvate with the GTP measured as described above:
<UP>GDP</UP>+<UP>phosphoenolpyruvate</UP> <LIM><OP><ARROW>→</ARROW></OP><UL><UP>pyruvate kinase</UP></UL></LIM><UP> GTP</UP>+<UP>pyruvate</UP>
<UP><SC>Reaction</SC> 3</UP>

Because the final product is again emitted light, this assay is also sensitive to 1 fmol. The reaction mixture was incubated for 30 min at 30 °C and contained in a final volume of 15 µl of 50 mM glycine, pH 7.8, 10 mM dithiothreitol, 8 mM MgSO4, 50 µM phosphoenolpyruvate, 3 milliunits of pyruvate kinase, and 5 µl of sample or GDP standard. It should be noted that this assay measures the sum of GTP + GDP; thus, the amount of GTP in the sample must be subtracted from the amount of GTP + GDP to yield the amount of GDP. DNA was measured by a standard fluorescence method using the fluorescent dye bisbenzimidazole, and protein was measured by the Bradford method. The amounts of GDP and GTP in the samples are determined from standard curves prepared with each set of samples and the data are expressed as femtomoles of GTP or GDP per microgram DNA or milligram protein in the cell lysate (40).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Detection of Recombinant Ad5-p85N-SH2 or Wild-type Virus by Multiplex PCR Analysis-- Multiplex PCR amplification of the viral DNA was performed using E1A and E2B specific primers as described previously (31). The E1A DNA (indicative of wild-type virus) was not detected from any plaque-purified recombinant Ad5-p85N-SH2 (Fig. 1A, top panel, lanes 2-6), but was specifically detected when DNA from the wild-type infected cell cultures was used as a template (Fig. 1A, lane 7). These results indicate that the recombinants were free of wild-type virus contamination. To further confirm the presence of recombinant cDNAs in E2B PCR positive clones, the Ad5-p85N-SH2 virus DNAs were PCR amplified with specific primers derived from the Ad5 polylinker (5' and 3' of the cloning site) and with cDNA specific primers named 1 and 2, respectively (see "Experimental Procedures"). A 386-bp cDNA fragment was detected from the p85N-SH2 domain clones (Fig. 1B, bottom panel, lanes 2-6), indicating the presence of recombinant DNA. No PCR product was detected in either the control or the wild-type infected cell culture DNA (Fig. 1B, lanes 1 and 7, respectively).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 1.   Detection of recombinant p85N-SH2 or wild-type virus in cell culture medium by PCR amplification of the viral DNA. DNA templates for PCR were extracted from the supernatant of the culture medium (350 µl) of the 293 cells that were infected with each plaque isolates/viruses (clones 1-5) at an m.o.i. of 50 pfu/ml. A (top panel), a multiplex PCR was performed on a tenth of virus DNA using E1A and E2B region specific primers. The E1A DNA (indicative of wild-type virus) was not detected from the five plaque-purified recombinant Ad5 p85N-SH2 (lanes 2-6) but was specifically detected when the DNA template from the wild-type infected cell culture was used as a template (lane 7). These results indicate that the recombinants were free of wild-type virus contamination. B (bottom panel), the recombinant Ad5 p85N-SH2 virus DNA (clones 1-5) were PCR-amplified with cDNA specific primers. A 386-bp fragment was detected in all the clones containing the recombinant Ad5 p85N-SH2 (lanes 2-6) but was not detected in the wild-type infected cell culture DNA (lane 7).

Northern and Western Blot Analysis of Overexpressed p85N-SH2 mRNAs and Proteins-- Northern blot analysis was used to confirm the expression of p85N-SH2 mRNAs in 293 cells (cells used for isolation of the recombinant adenoviruses) and HIRcB cells following infection at an m.o.i. of 1 and 10 pfu/cell of Ad5-p85N-SH2 (clones 2 and 4) adenovirus. The filter was hybridized with a 386-bp cDNA fragment of p85N-SH2 as a probe. Densitometric scanning of the blot revealed that treatment of the HIRcB cells (Fig. 2A, lanes 2 and 3) and 293 (lanes 3 and 4) cells with Ad5-p85N-SH2 resulted in a 20-100-fold increase in mRNA levels of the p85N-SH2 domain of PI 3-kinase relative to the uninfected cells (lane 1).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 2.   A, Northern blot analysis of overexpression of p85N-SH2 mRNA in 293 and HIRcB cells. Total RNA (15 µg) isolated from control (uninfected) and Ad5 p85N-SH2-infected 293 and HIRcB cells was electrophoresed on a 1% agarose, 6.6% formaldehyde gel and blotted onto a Hybond-N+ membrane. The filter was hybridized with a 386-bp fragment of p85N-SH2 cDNA as a probe. The autoradiograph was obtained after a 6-h exposure. Ctrl, control. B, expression of p85N-SH2 protein in 3T3-L1 adipocytes. Cells were infected with the p85N-SH2 expressing adenovirus at 10 and 50 m.o.i. for 12-16 h. After 3 days, 60 µg of protein were analyzed for expression by Western blotting using a monoclonal anti-Myc antibody. Immunoreactivity corresponding to the Myc epitope tag at the N terminus of the recombinant p85N-SH2 is indicated by arrow on the right side. The results shown are representative of several independent experiments on cells from separate infections.

The differentiated 3T3-L1 adipocytes were infected with the same clones of the p85N-SH2 expressing adenovirus at the indicated m.o.i. for 16 h and protein expression was examined 48 h later by Western blotting. Fig. 2B shows the results of an anti-Myc blot. Specific bands appeared at 18-20 kDa for the Myc-tagged p85N-SH2 protein in a viral dose-dependent manner.

Studies of HIRcB Fibroblasts: IRS-1-associated PI 3-Kinase Activity-- It is well established that tyrosine phosphorylated IRS-1 associates with and activates PI 3-kinase (1, 5, 6). Therefore, we measured IRS-1-associated PI 3-kinase activity in p85N-SH2-overexpressing HIRcB cells. In theory, the p85-derived N-SH2 domain should competitively inhibit interactions between the SH2 domain of endogenous p85 and its protein partners. To assess this, whole cell lysates from insulin-treated HIRcB fibroblasts overexpressing p85N-SH2 proteins were subjected to immunoprecipitation with anti IRS-1 antibody and PI 3-kinase activity was determined in the precipitates. In control cells, insulin stimulation resulted in a 25-30-fold increase in IRS-1-associated PI 3-kinase (Fig. 3) and this effect was unchanged in Ad5-lacZ- or Ad5-CMV-infected cells (data not shown). Overexpression of increasing amounts of the p85N-SH2 domain led to a dose-dependent inhibition of IRS-1-associated PI 3-kinase activity (Fig. 3). These results are consistent with the hypothesis that the overexpressed p85N-SH2 protein behaves in a dominant negative manner, interfering with the interactions of endogenous p85 with phosphorylated IRS-1.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of Ad5p85N-SH2 overexpression on insulin-stimulated PI3-kinase activity in HIRcB cells. Cells were infected with Ad5p85N-SH2 for 1 h at room temperature and grown in medium containing heat-inactivated serum (2%) for 48 h. Serum-starved (16 h) cells were incubated in the absence (basal) or presence of insulin (100 ng/ml) for 10 min, lysed, and subjected to immunoprecipitation with antibodies to IRS-1. The washed immunoprecipitates were assayed for PI 3-kinase activity with phosphatidylinositol as substrate, and the labeled PI 3-phosphate product (PI-3P) was resolved by thin-layer chromatography and visualized by autoradiography. This experiment was repeated four times with appropriate controls.

Effect of p85N-SH2 Domain on Insulin-stimulated DNA Synthesis-- To evaluate a more distal biological effect, insulin-stimulated cell cycle progression was measured by monitoring BrdUrd incorporation into newly synthesized DNA. Cells were plated on coverslips and infected with Ad5-p85N-SH2, and Ad5-beta -gal at m.o.i. of 2.0 and 10 pfu/cell, serum-starved for 36 h and then stimulated with insulin. As seen in Fig. 4, 45% of the uninfected cells underwent DNA synthesis in response to insulin and serum, respectively, and this response was not altered by Ad5-beta -gal infection. In contrast, overexpression of the p85N-SH2 domain completely inhibited insulin-stimulated DNA synthesis, showing that p85N-SH2 behaves in a dominant/negative fashion with respect to insulin-stimulated mitogenesis.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of DNA synthesis by overexpression of p85N-SH2 protein following infection with Ad5p85N-SH2 into HIRcB cells. Cells were infected with the indicated adenoviruses at increasing m.o.i. for 1 h at RT, serum-starved for 36 h, and stimulated with insulin (100 ng/ml) in the presence of BrdUrd for 16 h at 37 °C. They were then fixed and processed for immunofluorescence by sequential incubation with rat anti-BrdUrd antibody and rhodamine-conjugated anti-donkey antibody. Cells were counterstained with Hoechst stain to visualize nuclei. BrdUrd-incorporated cells were identified by the nuclear red rhodamine staining. An average of 200 cells per coverslip were counted. Results are expressed as the percentages ± S.E. of stained cells exhibiting nuclear fluorescence from three different experiments.

Studies in 3T3-L1 Adipocytes-- Effects of Overexpression of p85N-SH2 Domain on Insulin-induced PI 3-kinase Activation. 3T3-L1 adipocytes provide an excellent in vitro model system to study the metabolic actions of insulin. As seen in Fig. 2, these cells can be readily infected with adenoviral vectors, allowing us to examine the effect of p85N-SH2 domain expression in these cells. No differences in the extent of insulin-induced tyrosine phosphorylation of the insulin receptor or IRS-1 were detected in cell lysates from uninfected 3T3-L1 adipocytes or those expressing p85N-SH2 domain (data not shown). However, insulin-stimulated PI 3-kinase activity in anti-IRS-1 immunoprecipitates was markedly attenuated in 3T3-L1 adipocytes expressing p85N-SH2 domain compared with control or noninfected cells (Fig. 5A). Thus, in control cells, insulin led to a 10-15-fold increase in IRS-1-associated PI 3-kinase activity, which was markedly inhibited by expression of the p85N-SH2 domain in a dose-dependent manner. At 50 m.o.i., the insulin-induced PI 3-kinase activity was almost completely abolished. In contrast, infection of the 3T3-L1 adipocytes with Ad5-CMV was without effect. Pretreatment of cells with 100 nM wortmannin for 30 min prior to insulin stimulation resulted in ~80% reduction in IRS-1-associated PI 3-kinase activity (data not shown).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 5.   A, effects of Ad5p85N-SH2 overexpression on insulin-stimulated PI3-kinase activity in 3T3-L1 adipocytes. Cells were infected with Ad5p85N-SH2 for 16 h at 37 °C and grown in medium containing heat-inactivated serum (2%) for 48 h. Serum-starved (16 h) cells were incubated in the absence (basal) or presence of insulin (100 ng/ml) for 10 min, lysed, and subjected to immunoprecipitation with antibodies to IRS-1. The washed immunoprecipitates were assayed for PI 3-kinase activity with phosphatidylinositol as substrate, and the labeled PI 3-phosphate product (PI-3P) was resolved by thin-layer chromatography and visualized by autoradiography. This experiment was repeated four times with appropriate controls. Ctrl, control. B, cell lysates from 3T3-L1 adipocytes infected with control Ad5 or the p85N-SH2 expressing adenovirus, stimulated with or without insulin were subjected to immunoprecipitation with anti-phosphotyrosine antibody. The washed immunoprecipitates were assayed for PI 3-kinase activity as described above. Ctrl, control.

We also assessed PI3-K activity associated with phosphotyrosine residues in anti-phosphotyrosine immunoprecipitates from control and p85N-SH2-infected 3T3-L1 adipocytes in the presence and absence of insulin. In control cells, insulin stimulation resulted in ~15-fold increase in phosphotyrosine-associated PI3-K activity, which was completely inhibited by expression of the p85N-SH2 domain (Fig. 5B).

p21ras·GTP Loading-- Since the relationship between PI 3-kinase and Ras is a matter of debate, we examined the effect of PI 3-kinase inhibition on the insulin-induced stimulation of p21ras in 3T3-L1 adipocytes. Stimulation of 3T3-L1 adipocytes, infected with a control adenovirus (Ad5-CMV) with 100 ng/ml insulin for 10 min resulted in a 2-3-fold stimulation of p21ras activation (Fig. 6). Surprisingly, unstimulated cells overexpressing the p85N-SH2 protein showed a 2-3-fold higher, basal p21ras·GTP activity, which is similar to the insulin-induced state. Stimulation of these cells with insulin for 10 min did not have any further effect on p21ras·GTP loading.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of overexpression of the p85N-SH2 protein on Ras activation in 3T3-L1 adipocytes. Cells were infected with Ad5-Ctrl and Ad5-p85N-SH2 expressing adenoviruses at an m.o.i. of 50/cell in medium containing heat-inactivated serum (2%) for 12-16 h. Following infection, cells were serum-starved (16 h) and were incubated in the absence (basal) or presence of insulin (100 ng/ml) for 5 min, lysed. Cell lysated were assayed for GTP- and GDP-bound Ras as described under "Experimental Procedures." Data are expressed as femtomoles of guanine nucleotide per mg of cellular DNA and are the mean ± S.E. of three independent experiments. Ctrl, control.

Insulin-stimulated Activation of MAPK-- To investigate whether PI 3-kinase is required for the induction of MAPK activity, or alternatively, whether it plays an indirect role in regulating MAPK activation through its effect on Ras-GTP levels, we determined the activation state of MAPK in uninfected, control, or p85N-SH2-infected 3T3-L1 adipocytes in the presence and absence of insulin. Cell lysates were subjected to Western blot analysis with phosphospecific MAPK antibodies. This antibody detects the tyrosine-phosphorylated (position 204) activated form of p44 and p42 (ERK1 and ERK2) MAPK. In uninfected cells, insulin stimulated phosphorylation of MAPK by about 20-fold (Fig. 7A, lane 2). Overexpression of the p85N-SH2 domain led to a dose-dependent inhibition of both p44 and p42 MAPK phosphorylation and activation (Fig. 7A, lanes 3-6). Expression of MAPK was assessed by Western blotting with a polyclonal MAPK antiserum that recognizes both nonphosphorylated and phosphorylated forms and protein levels were not altered by infection with either the p85N-SH2 domain or Ctrl adenoviruses (Fig. 7B, lanes 1-6).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 7.   Effects of overexpression of the p85N-SH2 domain on insulin-stimulated MAPK phosphorylation and expression in 3T3-L1 adipocytes. Cells were infected with Ad5-p85N-SH2 expressing adenovirus at an m.o.i. of 10 and 50/cell in medium containing heat-inactivated serum (2%) for 12-16 h. Following infection, cells were serum-starved (16 h) and were incubated in the absence (basal) or presence of insulin (100 ng/ml) for 5 min, lysed, and, were subjected to SDS-PAGE and immunoblotted with phosphospecific MAPK antibody. Insulin stimulated phosphorylation of both p44 and p42 MAPKs as indicated (A). Phosphorylation of both p44 and p42 MAPKs were inhibited by overexpression of p85N-SH2 protein in a dose-dependent manner. This experiment was repeated twice. To detect the levels of expression of p44 and p42 MAPKs, the above filter was stripped and reblotted with anti-ERK1 antibody. There was no significant difference in the levels of expression between uninfected and infected 3T3-L1 adipocytes (B).

Insulin-stimulated Activation of p70S6K and AKT-- It has been shown that p70S6K is downstream of PI 3-kinase, and activation of this enzyme was determined by Western blot analysis of whole cell lysates with a phosphospecific p70S6K antibody that detects p70S6K only when phosphorylated at Thr-421/Ser-424 and does not cross-react with other phosphorylated protein kinases. As shown in Fig. 8A (upper panel, lane 2), stimulation of 3T3-L1 adipocytes with insulin resulted in activation of p70 S6 kinase, which was inhibited by pretreatment with rapamycin (Fig. 8A, upper panel, lane 1). The p85N-SH2-overexpressing cells demonstrate a 60-90% inhibition of insulin-induced p70S6K activation at 10 and 50 m.o.i, respectively (Fig. 8A, upper panel, lanes 5 and 7). Similar results were obtained when p70S6K activation was assessed by retarded migration on SDS-PAGE using anti p70S6K antibody. As shown in Fig. 8A (lower panel, lane 2), stimulation of cells with insulin resulted in activation of p70S6K, which was blocked by p85N-SH2 expression (Fig. 8A, lower panel, lanes 5 and 7).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 8.   A, effects of overexpression of the Ad5-p85N-SH2 protein on insulin-stimulated p70S6K activation in 3T3-L1 adipocytes. Cells were infected with Ad5-p85N-SH2 expressing adenovirus at 10 and 50 m.o.i. for 12-16 h. Serum-starved (16 h) cells were incubated in the absence (basal) or presence of insulin (100 ng/ml) for 30 min, lysed, and subjected to SDS-PAGE and immunoblotted with phospho-specific p70 S6 kinase antibody (upper panel). The above filter was stripped and reblotted with p70 S6 kinase antibody. Insulin stimulation of serine phosphorylation of p70 S6 kinase is detected by a retarded migration of the enzyme (lower panel, lane 2). Preincubation with 100 nM rapamycin for 30 min inhibited activation of p70 S6 kinase (lower panel, lane 1). Similarly, overexpression of PTB and SAIN proteins inhibited p70 S6 kinase activation in a dose-dependent manner (lower panel, lanes 4-7). This experiment was repeated twice. B, effects of overexpression of Ad5-p85N-SH2 protein on insulin-stimulated AKT activation in 3T3-L1 adipocytes. Whole cell lysates (60 µg) were prepared as described in A, were subjected to SDS-PAGE and immunoblotted with AKT antibody. Insulin stimulation of serine phosphorylation of AKT is detected by a retarded migration of the enzyme (lane 2). Preincubation with 100 nM wortmannin for 30 min inhibited activation of of AKT (lane 1). Overexpression of the p85N-SH2 protein (lanes 4-7) inhibited insulin-induced AKT activation (lanes 5 and 7). This experiment was repeated three times. Ctrl, control.

AKT (PKB) is also activated by insulin in a PI 3-kinase-dependent manner, and we assessed the degree of AKT activation in cell lysates, derived from insulin-stimulated 3T3-L1 cells as determined by retarded migration on SDS-PAGE (Fig. 8B, lane 2). Insulin treatment stimulated an AKT mobility shift, which was inhibited by wortmannin or p85N-SH2 expression (Fig. 8B, lanes 1, 5, and 7, respectively). These findings suggest that IRS-1-associated PI 3-kinase activity is necessary for insulin stimulation of p70S6K and for AKT activation.

Insulin-stimulated Glucose Transport-- Cells were infected with Ad5-p85N-SH2, or Ad5-CMV and 2-DOG uptake was measured 48 h later. As seen in Fig. 9A, insulin led to an 8-fold increase in 2-DOG uptake, and this was not affected by Ad5-CMV infection. p85N-SH2 expression at 20 and 50 m.o.i. markedly inhibited insulin-stimulated 2-DOG uptake. Expression of the p85N-SH2 also led to a slight decline in the basal 2-DOG. Viral mediated expression of the unrelated Shc SH2 domain had no effect on basal or insulin-stimulated glucose uptake (data not shown). To further evaluate this finding, additional experiment was performed in which insulin dose-response studies were carried out in control, Ad5-p85N-SH2-, and Ad5-CMV-infected cells. As shown in Fig. 9B, insulin-mediated glucose transport was inhibited by p85N-SH2, while control adenovirus was without effect.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 9.   A, inhibition of 2-deoxyglucose transport in 3T3L1 adipocytes infected with increasing m.o.i. of adenovirus expressing p85N-SH2. Differentiated 3T3-L1 adipocytes were infected with Ad5-p85N-SH2 or Ad5-ctrl at the indicated m.o.i. for 16 h at 37 °C and grown in medium containing heat-inactivated serum (2%) for 48 h. Serum- and glucose-deprived cells were incubated in alpha -MEM in the absence (basal) or presence of 100 ng/ml insulin for 1 h at 37 °C. Cells were then washed with glucose-free media, and 2-deoxyglucose uptake was measured. Each measurement was performed in duplicate. Infection of differentiated 3T3-L1 adipocytes with Ad5-p85N-SH2 resulted in a viral dose-dependent inhibition of insulin-stimulated percent incorporation of 2-deoxyglucose transport. Control Ad5 virus had no effect on glucose transport. Data are representative of four different observations ± S.E., and each value was corrected for protein. B, inhibition of 2-deoxyglucose transport in 3T3L1 adipocytes as a function of insulin concentration. Differentiated 3T3-L1 adipocytes were infected with 50 m.o.i. of Ad5-p85N-SH2 for 16 h at 37 °C and grown in medium containing heat-inactivated serum (2%) for 48 h. Serum- and glucose-deprived cells were incubated in alpha -MEM in the absence (basal) or presence of 1, 10, and 100 ng/ml insulin for 1 h at 37 °C. Cells were then washed in glucose-free media, and 2-deoxyglucose uptake was measured. Each measurement was performed in duplicate. Insulin stimulated percent incorporation of 2-deoxyglucose in 3T3-L1 adipocytes in a dose-dependent manner, which was inhibited by overexpression of the p85N-SH2 protein. Control Ad5 virus had no effect on glucose transport. Data are representative of four different observations. C, effect of co-expression of p110C and p85N-SH2 expressing adenoviruses on 2-deoxyglucose transport in 3T3L1 adipocytes. Differentiated 3T3-L1 adipocytes were infected with 20 and 60 m.o.i. of Ad5-p85N-SH2 and Ad5-p110C (a membrane-targeted, p110 subunit of PI 3-kinase), respectively, either individually or in combination, for 16 h at 37 °C and grown in medium containing heat-inactivated serum (2%) for 48 h. Serum- and glucose-deprived cells were incubated in alpha -MEM in the absence (basal) or presence of 100 ng/ml insulin for 1 h at 37 °C. Cells were then washed in glucose-free media, and 2-deoxyglucose uptake was measured. Each measurement was performed in duplicate. Data are representative of three different observations ± S.E.

Co-expression of p110CAAX Rescues 2-DOG Uptake Inhibited by the p85N-SH2 Protein-- The effect of coexpression of p85N-SH2 domain and a membrane-targeted, p110 subunit of PI 3-kinase (p110C) on 2-deoxyglucose uptake in 3T3-L1 adipocytes is shown in Fig. 9C. Insulin stimulated glucose transport about 8-fold in uninfected cells (Fig. 9C). Overexpression of a membrane-targeted (by C-terminal prenylation), p110 subunit of PI 3-kinase (p110C)2 stimulated glucose transport to the same extent as insulin, and addition of insulin had no further effect. The p85N-SH2 blocks insulin induced 2DOG uptake; however, co-expression of p110C with p85N-SH2 rescued 2-DOG uptake by ~90% without any added insulin.

Glycogen Synthase Activity-- Fig. 10 shows glycogen synthase activity in differentiated 3T3-L1 adipocytes. Glucose 6-phosphate-independent activity is expressed as a percentage of total glycogen synthase activity. In both nontransfected (not shown) and Ad5-CMV (control)-infected cells, insulin stimulated glycogen synthase activity ~3-fold. Preincubation of cells with 30 µM MEK inhibitor (PD 98059) had no effect on insulin induced glycogen synthase activity. The p85N-SH2 inhibited glycogen synthase activity by about 50%. These data suggest that activation of PI 3-kinase is necessary for activation of glycogen synthase, whereas MAPK does not appear to be involved.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 10.   Effect of overexpression of p85N-SH2 protein on glycogen synthase activity in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were infected with 50 m.o.i. of Ad5-Ctrl and Ad5-p85N-SH2 for 16 h at 37 °C and grown in medium containing heat-inactivated serum (2%) for 72 h. The cells were glucose- and serum-starved in DMEM containing 0.1% bovine serum albumin, 2 mM sodium pyruvate for 2.5 h, then incubated with or without 50 µM MEK inhibitor for 30 min, following which cells were stimulated with 200 ng/ml insulin for 30 min in 5 mM glucose-containing medium. After which the cells were scraped, sonicated, and centrifuged. The ability of the supernatant to stimulate incorporation of UDP-glucose into glycogen was determined in the presence and absence of glucose 6-phosphate (G-6-P). Results are expressed as mean ± S.E. of percentage of glycogen synthase index (% GSI) from three independent experiments. Ctrl, control.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Insulin stimulation leads to extensive tyrosine phosphorylation of IRS-1. Phosphorylated IRS-1 binds to the SH2 domains of the p85 subunit of PI 3-kinase and activates its p110 subunit, and this is a major mechanism by which insulin stimulates this enzyme. Several lines of evidence suggest that PI 3-kinase is involved in mediating mitogenic effects of various growth factors (2, 5, 42) and is a necessary molecule for insulin stimulation of glucose transport (18-23). Despite a great deal of information on both the structure and function of PI 3-kinase, the precise mechanism of its involvement in mediating insulin signaling is not fully understood.

In the current study, we have extensively evaluated the role of PI 3-kinase activity in a diverse array of insulin actions. Our approach is based on the hypothesis that cellular overexpression of the N-SH2 domain of the p85 subunit would competitively inhibit complex formation between endogenous PI 3-kinase and its SH2 domain binding targets such as IRS-1, -2, -3, -4, the insulin receptor, and others. This in turn, will prevent insulin activation of PI 3-kinase enzymatic activity, allowing us to elucidate the biologic actions of this enzyme in insulin target cells such as 3T3-L1 adipocytes. Indeed our data show not only a marked inhibition of insulin-stimulated IRS-1-associated PI 3-kinase activity, but we find a complete blockade of insulin-stimulated anti-phosphotyrosine-associated PI 3-kinase activity, which would include the non-IRS-1-associated activity. Predictably, and in agreement with previous findings, inhibition of PI 3-kinase activity resulted in abrogation of insulin's effects on glucose uptake and DNA synthesis (12-17). Other major findings of these experiments are that inhibition of PI 3-kinase activity resulted in inhibition of glycogen synthase activity and stimulation of MAPK activation by insulin. In contrast, overexpression of the p85N-SH2 protein led to a 2-fold increase in basal, insulin-independent GTP-bound levels of p21ras. However, insulin treatment did not further alter the levels of GTP-bound p21ras in these cells. Inhibition of the PI 3-kinase activity, also led to significant impairment of other downstream signaling effects of insulin such as Akt and p70 S6 kinase phosphorylation. These results lead to several predictions and conclusions.

The activation of MAPK by insulin depends on activation of Ras (1, 13). Tyrosine-phosphorylated Shc (12), and to a lesser extent IRS-1 (1, 5, 6), binds to the adaptor protein, Grb-2, which is preassociated with the guanine nucleotide exchange factor, Sos, that promotes the formation of the active GTP-bound state of Ras. Formation of GTP-bound Ras leads to activation of the protein serine/threonine kinase cascade including Raf-1 kinase, MEK and MAPK (1, 13). Recent studies using specific inhibitors of PI 3-kinase or constitutively active and dominant negative mutants of the enzyme, have yielded confusing, and potentially conflicting results suggesting that PI 3-kinase can be either downstream or upstream of Ras (26-30). In the present study, using 3T3-L1 adipocytes, we have demonstrated that inhibition of PI 3-kinase decreased insulin-induced activation of MAPK, although the levels of GTP-bound Ras were increased ~2-fold in the basal state. Thus, PI 3-kinase may be required for the activation of MAPK at a step independent of and downstream of Ras.

The importance of PI 3-kinase for activation of ERKs 1 and 2 has been controversial. Expression of activated forms of p110alpha has been reported to stimulate the MAPK pathway in one case (29), but not in others (32, 43-45). A recent study found that overexpression of the p110gamma isoform resulted in activation of ERKs 1 and 2, whereas p110alpha was without effect (45). Our findings indicating the involvement of PI 3-kinase in the activation of MAPK seem to be consistent with a recent report showing that treatment of 3T3-L1 adipocytes, either with wortmannin or LY294002, inhibited insulin-induced activation of Raf-1 and MAPKs with no effect on the formation of GTP-bound Ras (46). However, wortmannin did not affect epidermal growth factor-induced activation of Raf and MAPK in the same system, indicating that differential mechanisms to activate Raf-1 and MAPKs by insulin and epidermal growth factor exist in 3T3-L1 adipocytes. Very similar observations have been reported using rat adipocytes (47). However, the involvement of PI 3-kinase in MAPK activation appears to be cell type-specific, because wortmannin did not inhibit insulin-induced activation of MAPK in CHO cells in the above study (46).

As mentioned earlier, the relationship between PI 3-kinase and Ras is a matter of debate. Some observations indicate that PI 3-kinase could be upstream, downstream, or independent of Ras; these observations are perhaps related to cell-type differences (reviewed in Ref. 48). Our data reinforce the idea that PI 3-kinase is upstream and can activate the Ras pathway. However, our unexpected findings were the influence of overexpression of the p85N-SH2 domain of PI 3-kinase to stimulate formation of p21ras·GTP in 3T3-L1 adipocytes. PI 3-kinase and Ras form a complex, suggesting an intimate relation between the function of these molecules (28), and it can be argued that a loss of PI 3-kinase activity could disrupt basal Ras-p110 binding, which may be required for PI 3-kinase signaling.

It is known that insulin stimulates p21ras·GTP loading by increasing the guanine nucleotide exchange activity of Sos (49, 50). Return of p21ras into its inactive conformation is facilitated by GAP that hydrolyzes GTP to GDP. Therefore, overexpression of the p85N-SH2 domain of PI 3-kinase can stimulate formation of p21ras·GTP either by stimulating the guanine exchange activity of Sos or by diminishing the activity of GAP. Stimulation of Sos activity is unlikely because Langolis et al. (51) have shown that immunodepletion of PI 3-kinase from lysates of insulin-stimulated cells does not alter the activity level of the guanine nucleotide exchange factor Sos. Therefore, the most likely explanation for the increase in basal GTP-bound Ras in the p85N-SH2 expressing cells is that the p85N-SH2 depletes the pool of GAP in these cells. Indeed, in 3T3-L1 adipocytes, the p85 subunit of PI 3-kinase is already in excess compared with the p110 subunit, and it has been shown to interact with GAP (presumably via p62, a GAP-associated protein) (52). Overexpression of the p85N-SH2 peptide could titrate out cellular GAP by direct association, such that GAP is not available to hydrolyze p21ras·GTP. The elevated p21ras·GTP levels do not appear to affect MAPK activity, since we find that the p85N-SH2 protein inhibits insulin-induced MAPK phosphorylation in 3T3-L1 adipocytes. Therefore, the inhibitory effect of PI 3-kinase on the MAPK cascade most likely occurs at a level independent of Ras. Therefore, in these cells, insulin is able to stimulate MAPK via a Ras-independent pathway. These results are in agreement with the observations of Carel et al. (53), who also found that insulin activates MAPK by a Ras-independent pathway in 3T3-L1 adipocytes and by a Ras-dependent pathway in 3T3-L1 fibroblasts.

In an earlier report, we utilized an adenovirus system to express the PTB domain of IRS-1 in 3T3-L1 adipocytes. This led to a marked decrease in IRS-1-associated PI 3-kinase activity, but no inhibition of insulin-stimulated glucose transport (31). The current study further extends our earlier proposed hypothesis that complete blockade of PI 3-kinase activity (i.e. IRS-1 and the non-IRS-1-associated components) would be necessary to inhibit insulin-induced glucose transport. Indeed, we find that this is the case from these results. As shown in Fig. 5B, the dominant negative p85 completely blocks PI 3-kinase activity in the phosphotyrosine immunoprecipitates. The number of insulin receptor substrates is expanding rapidly, with the addition of IRS-2, -3, and -4 to the earlier insulin-substrates: IRS-1 and Shc. Among these, IRS-2 and IRS-3 (pp60) are tyrosine phosphorylated by insulin and bind to PI 3-kinase (7, 54). It is possible that insulin stimulates glucose transport by at least two parallel pathways, which may be interacting or redundant. The current data support the notion that inhibition of glucose transport results from blockade of a yet to be identified, non-IRS-1-associated PI 3-kinase activity. Consistent with this, studies by Kaburagi et al. (16) on fat cells derived from IRS-1 knockout mice, and in which IRS-2 is negligible, show only a 50% reduction in maximal insulin-stimulated glucose transport, indicating the existence of an IRS-1/2-independent, but PI 3-kinase-dependent pathway for transport stimulation (16). In addition, studies by Krook et al. (17) and Isakoff et al. (55) are also consistent with the notion that IRS-1 phosphorylation, and its associated PI 3-kinase activation, are not sufficient to initiate metabolic signaling, suggesting that additional insulin-derived metabolic inputs must exist.

We also examined additional targets of insulin action which are thought to be downstream of PI 3-kinase, to further explore the effects of PI 3-kinase inhibition. Akt, a serine/threonine kinase, is a downstream target of PI 3-kinase and is activated by a dual mechanism involving the binding of phosphatidylinositol 3,4-bisphosphate to its PH domain, as well as serine/threonine phosphorylation by one or more Akt kinases, which may themselves be stimulated by the lipid products of PI 3-kinase (56). Expression of a constitutively active Akt in rat adipocytes (57) and 3T3-L1 adipocytes (58) increases glucose uptake and GLUT4 translocation. Consistent with these findings, our data show that Akt activation is dependent on PI 3-kinase activity, since we find that pretreatment of 3T3-L1 adipocytes with wortmannin, a PI 3-kinase inhibitor, as well as overexpression of the dominant inhibitory p85N-SH2 protein, leads to an inhibition of insulin-induced serine/threonine kinase activity of Akt. In addition, insulin-induced glucose transport and glycogen synthase were inhibited when 3T3-L1 adipocytes were pretreated with wortmannin, or when the p85N-SH2 protein was overexpressed. Similarly, insulin-induced phosphorylation of another downstream target of PI 3-kinase, p70 S6 kinase, was inhibited by Rapamycin as well as by the dominant inhibitory p85N-SH2 protein. These results suggest a role for Akt as a PI 3-kinase-dependent upstream activator of glucose transport and/or a role for p70 S6 kinase as a PI 3-kinase-dependent upstream activator of glycogen synthase activity.

Our data on expression of the membrane-targeted p110C indicate that membrane localization of PI 3-kinase is critical for biologic functions, since this form of the p110 subunit leads to stimulation of 2-deoxyglucose transport similar to the insulin induced levels in 3T3-L1 adipocytes. Along similar lines, it has been shown in COS-7 cells, that targeting p110 to the membrane, either by N-terminal myristoylation or by C-terminal farnesylation, can stimulate p70 S6 kinase and Akt activity in the absence of insulin. Our results on co-expression of the p110C with the N-SH2 domain strongly support the idea that the p85N-SH2 protein specifically blocks insulin mediated PI 3-kinase activity, by competitively interfering with the targeting of p85 to its natural protein partners. Thus, although the functional activity of downstream signaling molecules, such as p70 S6 kinase, Akt, and GLUT4, are functionally blocked by expression of the p85N-SH2, the fact that the biologic activity can be rescued by co-expression of the N-SH2 domain with p110C demonstrates that the signaling pathways downstream of p85 targeting are intact and that the dominant/negative effects of the p85N-SH2 domain do not reflect nonspecific actions at other cellular loci.

Our studies also show that overexpression of the p85N-SH2 domain markedly inhibits insulin-stimulated glycogen synthase activity. This leads to the conclusion that PI 3-kinase stimulation is necessary for insulin activation of glycogen synthase. The molecular mechanisms by which glycogen synthase is regulated by insulin remains one of the crucial issues in insulin action. Insulin stimulates glycogen synthesis via a coordinated response involving activation of protein phosphatase 1, by phosphorylation of its G subunit and by a phosphorylation-induced inactivation of glycogen synthase kinase 3 (GSK3) (59, 60). It has been suggested that pp1 might be downstream of the MAPK pathway, but a number of reports have indicated that this is not the case (61). In addition, our own results show that the MEK inhibitor (PD098059) did not lead to a decrease in insulin stimulation of glycogen synthesis. Thus, it is unlikely that any effect of the p85N-SH2 protein on the MAPK pathway is mediating the inhibitory effect on glycogen synthesis. It has been reported that GSK3 is a downstream target of Akt, which, in turn, is dependent on PI 3-kinase activity (62). Thus, one potential interpretation of our results is that inhibition of PI 3-kinase, through the dominant/negative p85N-SH2 domain, prevents insulin-stimulated GSK3 phosphorylation, and that this leads to inhibition of glycogen synthesis. However, it has recently been shown that GSK3 expression is either very low, or not expressed, in 3T3-L1 adipocytes (63-65), making this possibility less likely. Thus, although the exact mechanism is unknown, our results clearly show that insulin-stimulated glycogen synthesis is dependent on proper targeting of PI 3-kinase, and this is consistent with other reports showing that insulin-stimulated glycogen synthesis can be inhibited by wortmannin or LY294002 (21, 66), both of which are relatively specific inhibitors of PI 3-kinase activity.

In conclusion, we have shown that overexpression of the p85N-SH2 domain in 3T3-L1 adipocytes inhibits a variety of insulin's ultimate biologic effects, and that this domain will also block insulin-stimulated DNA synthesis in fibroblasts. These results are consistent with our earlier findings, which suggested that a complete blockade of PI 3-kinase targeting to all of its cellular substrates (IRS-1 as well as non-IRS-1 targets) would be necessary for inhibition of AKT activation and glucose transport stimulation. We also find that in 3T3-L1 adipocytes, PI 3-kinase can regulate p21ras·GTP levels and that the dominant/negative effects of the p85 NSH2 domain on the MAP kinase pathway are exerted distal to the stimulatory effect of p21ras·GTP on the MAPK pathway.

    FOOTNOTES

* This work was supported by National Institutes of Health Research Grant R01 DK 36651 (to J. M. O.) and a grant from the Uehara Memorial Foundation (to K. E.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**  To whom correspondence should be addressed: Dept. of Medicine (0673), University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0673. Tel.: 619-534-6651; Fax: 619-534-6653.

1 The abbreviations used are: PI, phosphatidylinositol; GAP, GTPase-activating protein; GLUT4, insulin-responsive glucose transporter; IRS, insulin receptor substrate; MAP, microtubule-associated protein; MAPK, microtubule-associated protein kinase; p85, 85-kDa regulatory subunit of PI 3-kinase; BrdUrd, bromodeoxyuridine; m.o.i., multiplicity of infection; bp, base pair(s); beta -gal, beta -galactosidase; 2-DOG, 2-deoxyglucose; SH, Src homology; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; alpha -MEM, alpha -minimal essential medium; PCR, polymerase chain reaction; DMEM, Dulbecco's modified Eagle's medium; ERK, extracellular signal-regulated kinase; MEK, MAP kinase/ERK kinase; GSK3, glycogen synthase kinase 3.

2 K. Egawa, P. M. Sharma, N. Nakashima, Y. Huang, E. Huvar, G. Boss, J. Downward, and J. M. Olefsky, manuscript in preparation.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Cheatham, B., and Kahn, C. R. (1995) Endocr. Rev. 16, 117-142[Medline] [Order article via Infotrieve]
  2. Braselmann, S., Palmer, T. M., and Cook, S. J. (1997) Curr. Biol. 7, R470-R473[Medline] [Order article via Infotrieve]
  3. Dhand, R., Hara, K., Hiles, I., Bax, B., Gout, I., Panayotou, G., Fry, M. J., Yonezawa, K., Kasuga, M., and Waterfield, M. D. (1994) EMBO J. 13, 511-521[Abstract]
  4. Baltensperger, K., Kozma, L. M., Jaspers, S. R., and Czech, M. P. (1994) J. Biol. Chem. 269, 28937-28946[Abstract/Free Full Text]
  5. Myers, M. G., Jr., and White, M. F. (1995) Trends Endocrinol. Metab. 6, 209-215[CrossRef]
  6. Waters, S. B., and Pessin, J. E. (1996) Trends Cell Biol. 6, 1-4[CrossRef]
  7. Lavan, B. E., Lane, W. S., and Lienhard, G. E. (1997) J. Biol. Chem. 272, 11439-11443[Abstract/Free Full Text]
  8. Lavan, B. E., Fantin, V. R., Chang, E. T., Lane, W. S., Keller, S. R., and Lienhard, G. E. (1997) J. Biol. Chem. 272, 21403-21407[Abstract/Free Full Text]
  9. Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X.-J., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., and White, M. F. (1992) EMBO J. 11, 3469-3479[Abstract]
  10. Backer, J. M., Myers, M. G., Jr., Sun, X.-J., Chin, D. J., Shoelson, S. E., Miralpeix, M., and White, M. F. (1993) J. Biol. Chem. 268, 8204-8212[Abstract/Free Full Text]
  11. Fry, M. J. (1994) Biochim. Biophys. Acta 1226, 237-268[Medline] [Order article via Infotrieve]
  12. Sasaoka, T., Draznin, B., Leitner, J. W., Langlois, J. W., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 10734-10738[Abstract/Free Full Text]
  13. Jhun, B. H., Rose, D. W., Seely, B. L., Rameh, L., Cantley, L., Saltiel, A. R., and Olefsky, J. M. (1994) Mol. Cell. Biol. 14, 7466-7475[Abstract]
  14. Jhun, B. H., Meinkoth, J. L., Leitner, J. W., Draznin, B., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 5699-5704[Abstract/Free Full Text]
  15. Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203-212[Medline] [Order article via Infotrieve]
  16. Kaburagi, Y., Satoh, S., Tamemoto, H., Yamamoto-Honda, R., Tobe, K., Veki, K., Yamauchi, T., Kono-Sugita, E., Sekihara, H., Aizawa, S., Cushman, S. W., Akanuma, Y., Yazaki, Y., and Kadowaki, T. (1997) J. Biol. Chem. 272, 25839-25844[Abstract/Free Full Text]
  17. Krook, A., Moller, D. E., Dib, K., and O'Rahilly, S. (1996) J. Biol. Chem. 271, 7134-7140[Abstract/Free Full Text]
  18. Conricode, K. M. (1995) Biochem. Mol. Biol. Int. 36, 835-843[Medline] [Order article via Infotrieve]
  19. Margalet-Sanchez, V., Goldfine, I. D., Vlahos, C. J., and Sung, C. K. (1994) Biochem. Biophys. Res. Commun. 204, 446-452[CrossRef][Medline] [Order article via Infotrieve]
  20. Berger, J., Hayes, N., Szalkowksi, D. M., and Zhang, B. (1994) Biochem. Biophys. Res. Commun. 205, 570-576[CrossRef][Medline] [Order article via Infotrieve]
  21. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911[Abstract]
  22. Okada, T., Kawano, Y., Sakakibara, T., Hazeki, O., and Ui, M. (1994) J. Biol. Chem. 269, 3568-3573[Abstract/Free Full Text]
  23. Clarke, J. F., Young, P. W., Yonezawa, K., Kasuga, M., and Holman, G. D. (1994) Biochem. J. 300, 631-635[Medline] [Order article via Infotrieve]
  24. Tanti, J.-F., Grillo, S., Gremeaux, T., Coffer, P. J., Van Obberghen, E., and Marchand-Brustel, Y. L. (1997) Endocrinology 138, 2005-2010[Abstract/Free Full Text]
  25. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. (1996) J. Biol. Chem. 271, 31372-31378[Abstract/Free Full Text]
  26. Yamauchi, K., Holt, K., and Pessin, J. E. (1993) J. Biol. Chem. 268, 14597-14600[Abstract/Free Full Text]
  27. Hara, K., Yonezawa, K., Sakaue, H., Ando, A., Kotani, K., Kitamura, T., Kitamura, Y., Ueda, H., Stephens, L., Jackson, T. R., Hawkins, P. T., Dhand, R., Clark, A. E., Holman, G. D., Waterfield, M. D., and Kasuga, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 9, 7415-7419
  28. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532[CrossRef][Medline] [Order article via Infotrieve]
  29. Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., and Williams, L. W. (1995) Science 268, 100-102[Medline] [Order article via Infotrieve]
  30. Sjolander, A., Yamamoto, K., Huber, B. E., and Lapetina, E. G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7908-7912[Abstract]
  31. Sharma, P. M., Egawa, K., Gustafson, T. A., Martin, J. L., and Olefsky, J. M. (1997) Mol. Cell. Biol. 17, 7386-7397[Abstract]
  32. Frevert, E. U., and Khan, B. B. (1997) Mol. Cell. Biol. 17, 190-198[Abstract]
  33. Gluzman, Y., Reichl, H., and Solnick, D. (1982) in Eucaryotic Viral Vectors (Gluzman, Y., ed), pp. 187-192, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  34. McGrory, W. J., Bautista, D. S., and Graham, F. L. (1988) Virology 163, 614-617[Medline] [Order article via Infotrieve]
  35. Zhang, W.-W., Koch, P. E., and Roth, J. A. (1995) BioTechniques 18, 444-447[Medline] [Order article via Infotrieve]
  36. Sharma, P. M., Bowman, M., Yu, B.-F., and Sukumar, S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9931-9935[Abstract/Free Full Text]
  37. Ruderman, N. B., Kapeller, R., White, M. F., and Cantley, L. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1411-1415[Abstract]
  38. Klip, A., Li, G., and Logan, W. J. (1984) Am. J. Physiol. 247, E291-E296[Abstract/Free Full Text]
  39. Guinovart, J. J., Salavert, A., Massague, J., Ciudad, C. J., Salsas, E., and Itarte, E. (1979) FEBS Lett. 106, 284-288[CrossRef][Medline] [Order article via Infotrieve]
  40. Scheele, J. S., Rhee, J. M., and Boss, G. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1097-1100[Abstract]
  41. Deleted in proof
  42. Kapeller, R., and Cantley, L. C. (1994) BioEssays 16, 565-576[Medline] [Order article via Infotrieve]
  43. Klippel, A., Reinhard, C., Kavanaugh, W. M., Apell, G., Escobedo, M-A., and Williams, L. W. (1996) Mol. Cell. Biol. 16, 4117-4127[Abstract]
  44. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evans, G. (1997) Nature 385, 544-548[CrossRef][Medline] [Order article via Infotrieve]
  45. Lopez-Ilasaca, M., Crespo, P., Pellici, P. G., Gutkind, J. S., and Wetzker, R. (1997) Science 275, 394-397[Abstract/Free Full Text]
  46. Suga, J., Yoshimasa, Y., Yamada, K., Yamamoto, Y., Inoue, G., Okamoto, M., Hayashi, T., Shigemoto, M., Kosaki, A., Kuzuya, H., and Nakao, K. (1997) Diabetes 46, 735-741[Abstract]
  47. Liu, H., Lee, J., Kublaoui, B., Pilch, P. F. (1996) Diabetes 45, Suppl. 2, 119A
  48. Carpenter, C. L., and Cantley, L. C. (1996) Curr. Opin. Cell Biol. 8, 153-158[CrossRef][Medline] [Order article via Infotrieve]
  49. Draznin, B., Chang, L., Leitner, J. W., Takata, Y., and Olefsky, J. M. (1993) J. Biol. Chem. 268, 19998-20001[Abstract/Free Full Text]
  50. Medema, R. H., deVries-Smits, A. M. M., van der Zon, G. C. M,., Maassen, J. A, and Bos, J. L. (1993) Mol. Cell. Biol. 13, 155-162[Abstract]
  51. Langolis, J., Leitner, W., Medth, T., Sasaoka, T., Olefsky, J. M., and Draznin, B. (1995) Endocrine 3, 475-479
  52. DePaolo, D., Reusch, J. E.-B., Carel, K., Bhuripanyo, P., Leitner, J. W., and Draznin, B. (1996) Mol. Cell. Biol. 16, 1450-1457[Abstract]
  53. Carel, K., Kummer, J. L., Schubert, C., Leitner, J. W., Heidenreich, K. A., and Draznin, B. (1996) J. Biol. Chem. 271, 30625-30630[Abstract/Free Full Text]
  54. Tobe, K., Tamemoto, H., Yamauchi, T., Aizawa, S., Yazaki, Y., and Kadowaki, T. (1995) J. Biol. Chem. 270, 5698-5701[Abstract/Free Full Text]
  55. Isakoff, S. J., Taha, C., Rose, E., Marcusohn, J., Klip, A., and Skolnik, E. Y. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10247-10251[Abstract]
  56. Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., and Hawkins, P. T. (1997) Science 277, 567-570[Abstract/Free Full Text]
  57. Tanti, J.-F., Gremeaux, T., Grillo, S., Calleja, V., Klippel, A., Williams, L. T., Van Obberghen, E., and Le Marchand-Brustel, Y. (1996) J. Biol. Chem. 271, 25227-25232[Abstract/Free Full Text]
  58. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. (1996) J. Biol. Chem. 271, 31372-31378[Abstract/Free Full Text]
  59. Parker, P. J., Caudwell, F. B., and Cohen, P. (1993) Eur. J. Biochem. 130, 227-234[Medline] [Order article via Infotrieve]
  60. Shulman, R. G., Bloch, G., and Rothman, D. L. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8535-8542[Abstract]
  61. Lawrence, J. C., and Roach, P. J. (1997) Diabetes 46, 541-547[Abstract]
  62. Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
  63. Benjamin, W. B., Pentyala, S. N., Woodgett, J. R., Hod, Y., and Marshak, D. (1994) Biochem. J. 300, 477-482[Medline] [Order article via Infotrieve]
  64. Cross, D. A. E., Watt, P. W., Shaw, M., van der Kaay, J., Downes, C. P., Holder, J. C., and Cohen, P. (1977) FEBS Lett. 406, 211-215[CrossRef]
  65. Moule, S. K., Welsh, G. I., Edgell, N. J., Foulstone, E. J., Proud, C. G., and Denton, R. M. (1977) J. Biol. Chem. 272, 7713-7719[Abstract/Free Full Text]
  66. Shepherd, P. R., Nave, B. T., and Siddle, K. (1995) Biochem. J. 305, 25-28[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.